Abiopharma

🔍 LANGE LOUIS G (Executive)

Company: NewAmsterdam Pharma Co N.V. (NAMS)

Report Date: 2026-01-07

Detailed Transactions and Holdings:

• Acquired 3,400 shares of Ordinary Shares (Direct)
  Date: 2026-01-07 | Code: A | equity_swap_involved: false | shares_owned_after: 10,360.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Acquired 15,300 shares of Option (right to buy) at $35.45 per share (Derivative)
  Date: 2026-01-07 | Code: A | Expires: 2036-01-07 | equity_swap_involved: false | shares_owned_after: 15,300.00 | transaction_form_type: 4 | Footnotes: F4

Footnotes:

• F1: Represents restricted stock units (RSUs), each representing a contingent right to receive one ordinary share. All of the RSUs will vest on the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.
• F2: Each RSU was granted on January 7, 2026 for no consideration.
• F3: The Reporting Person inadvertently reported the ownership of 3,102 ordinary shares issued upon vesting of RSUs on March 28, 2025 to his direct holdings. Such ordinary shares are held directly by LGLange III Trust DTD10 for the benefit of the Reporting Person. The Reporting Person subsequently corrected his indirect holdings on April 21, 2025, and the Reporting Person's indirect holdings reported on May 2, 2025 and June 3, 2025 are correct. This Form 4 reflects the Reporting Person's correct direct holdings.
• F4: All of the ordinary shares underlying the option will vest on January 2, 2027, the one-year anniversary of the vesting start date, subject to the Reporting Person's continued service through such date.